CFS Clinical Launches Business Intelligence Platform to Aid Decision-Making For Clinical Trials
CFS Clinical (CFS), a provider focused on the business and financial management activities for clinical trials, announced the launch of its upgraded technology platform and new tax consulting services.
The InSite™ technology platform offers transparency for clinical trial operations, with reporting capabilities offering further visibility into investigator grant payments and study startup – including grant spend forecasting and modeling, Sunshine & global transparency compliance, enterprise site profiling, and more.
“CFS Clinical is the leader in our space and has always been a pioneer in clinical business operations. By adapting our solutions to the changing needs of sponsors, CROs, and sites, CFS continues to lead the way in transforming the business of clinical trials,” says Kevin Williams MBA/MS, Vice President of Corporate Development and Marketing for CFS Clinical.
In addition to the expanded business intelligence capabilities, CFS Clinical officially launched its Tax Consulting Service in January to help clients sort out the vast complexities of paying investigators globally.
“VAT rates range from 10-29%, and those rates are applied to millions of dollars of global grant payments.” states April Mulroney CPA, CA, Vice President of Global Tax, Treasury and Client Services based in CFS’s UK office. “CFS experts formalized this unique service to help our clients minimize financial risk and manage tax exposure on the largest line item in their clinical trial budget – the grant payments.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
